

Ernest A. Harrison, Jr., (1) and Kenner C. Rice\*

Laboratory of Chemistry, National Institute of Arthritis, Metabolism and Digestive Diseases, National  
Institutes of Health, Bethesda, MD 20014

Michael E. Rogers


Department of Pharmaceutical Chemistry, Medical College of Virginia, Virginia Commonwealth  
University, Richmond, VA 23298

Received September 27, 1976

Synthesis of five 2-aryl-3-hydroxythieno[2,3-*b*]quinoline 1,1-dioxides (**38-42**) from 3-formylquinoline-2-thiol (**3**) via a facile oxidation-cyclization sequence is reported. Reaction of appropriate benzyl chlorides with the thiol (**3**) in the presence of sodium methoxide gave excellent yields of the corresponding benzyl 2-(3-formylquinolyl) sulfides (**4-8**). Direct oxidation of these sulfides to the corresponding sulfones (**23-27**) was effected with excess sodium chlorite in aqueous pyridine. Esterification of these sulfone-acids followed by brief treatment of the resulting esters **28-32** with sodium methoxide gave the desired compounds **38-42** after acidification. The benzyl 2-(3-formylquinolyl) sulfides were also selectively oxidized to the corresponding sulfoxides (**13-17**). Thus sodium chlorite has proved to be an effective reagent for the stepwise oxidation of sulfides to sulfones. The title compounds were potent inhibitors of cyclic AMP phosphodiesterase, but failed to display significant antiinflammatory effects in the carrageenan rat paw edema test or significant activity in the phenylquinone induced writhing test for analgesia.


*J. Heterocyclic Chem.*, 14, 909 (1977)

We have recently become interested in the synthesis of novel heterocyclic systems for evaluation of their therapeutic potential, particularly as nonsteroidal antiinflammatory agents. In conjunction with this program, we wish to report results of our initial synthetic and biological studies concerning compounds of the thieno[2,3-*b*]quinoline series. Aside from a multistep entry into this series from a butyrolactone derivative reported some time ago (2), and several simple representatives prepared more recently (3-5), the chemistry of this ring system has remained uninvestigated. Our interest in this ring system stems from the reported (6) antiinflammatory activity shown by a number of 2-arylbenzo[*b*]thiophene-3(2*H*)-one 1,1-dioxides (**1**) and two 2-arylnaphtho[2,3-*b*]thiophene-3(2*H*)one 1,1-dioxides (**2**). We now report synthesis, *via* a facile oxidation-cyclization procedure, of



a group of 2-aryl-3-hydroxythieno[2,3-*b*]quinoline 1,1-dioxides (**38-42**) which can be viewed as aza congeners of the antiinflammatory naphtho[2,3-*b*]thiophene derivatives (**2**). We also report biological evaluation of these compounds for *in vivo* antiinflammatory activity in the carrageenan rat paw edema test, analgesic activity in the phenylquinone induced writhing test, and *in vitro* inhibition of bovine heart cyclic AMP phosphodiesterase.


Scheme 1



Our synthetic approach to the desired compounds (**38-42**, Table 4) proceeded through intermediates similar to those employed in one route (6) to the antiinflammatory compounds **1** and **2**. We envisioned (Scheme I) treatment of the readily available sodium salt of **3** with the corresponding benzyl chlorides to provide **4-8**, since **4** had previously been prepared by this method (3). It seemed likely to us that the oxidation states of **4-8** could be adjusted to give, after esterification of an appropriate intermediate, the sulfone-esters **28-32**. Although two

Table 1

Benzyl 2-(3-Formylquinolyl) Sulfides and Other Related Sulfides




Compound	R <sub>1</sub>	R <sub>2</sub>	Yield % (a)	M.p. °C (Recrystallization Solvent)	Formula	Analyses or Literature Melting Point			
						Calcd.	Found	Calcd.	Found
4	CHO	H	88	108-110 (Acetonitrile)	C <sub>17</sub> H <sub>13</sub> NOS	104° (b)			
5	CHO	4-Cl	91	143-145 (Benzene)	C <sub>17</sub> H <sub>12</sub> ClNOS	65.06	64.77	3.85	3.79
6	CHO	3-F	92	127-129 (Benzene)	C <sub>17</sub> H <sub>12</sub> FNOS	68.66	68.90	4.07	4.07
7	CHO	4-F	90	128-129 (Benzene)	C <sub>17</sub> H <sub>12</sub> FNOS	68.66	68.48	4.07	3.96
8	CHO	4-OCH <sub>3</sub>	92	108-110 (Acetonitrile)	C <sub>18</sub> H <sub>15</sub> NO <sub>2</sub> S	69.88	69.93	4.89	4.84
9	CO <sub>2</sub> H	H	98	266-268 dec. (DMSO-Acetic Acid) (c)	C <sub>17</sub> H <sub>13</sub> NO <sub>2</sub> S	69.13	69.20	4.44	4.65
10	CO <sub>2</sub> Me	H	92	129-131 (Acetonitrile)	C <sub>18</sub> H <sub>15</sub> NO <sub>2</sub> S	69.88	69.92	4.89	4.74
11	CO <sub>2</sub> H	4-OCH <sub>3</sub>	99	233-235 dec. (DMSO-Acetic Acid) (c)	C <sub>18</sub> H <sub>15</sub> NO <sub>3</sub> S	66.44	66.75	4.65	4.80
12	CO <sub>2</sub> Me	4-OCH <sub>3</sub>	88	146-148 (Acetonitrile)	C <sub>19</sub> H <sub>17</sub> NO <sub>3</sub> S	67.23	67.07	5.05	4.93

(a) Crude but essentially pure material. (b) Recrystallized by dissolving the dry acid in a small volume of DMSO and diluting with several volumes of acetic acid.

Table 2


Benzyl 2-(3-Carboxyquinolyl) Sulfoxides and Methyl Esters



Compound	R <sub>1</sub>	R <sub>2</sub>	Yield % (a)	M.p. °C (Recrystallization Solvent)	Formula	Analyses			
						Calcd.	Found	Calcd.	Found
13	H	H	96	200-203 dec. (DMSO-Acetic Acid) (b)	C <sub>17</sub> H <sub>13</sub> NO <sub>3</sub> S	65.58	65.86	4.21	4.20
14	H	4-Cl	85	187-190 dec. (DMSO-Acetic Acid) (b)	C <sub>17</sub> H <sub>12</sub> ClNO <sub>3</sub> S	59.04	59.30	3.50	3.66
15	H	3-F	88	207-209 dec. (DMSO-Acetic Acid) (b)	C <sub>17</sub> H <sub>12</sub> FNOS	61.99	61.61	3.67	3.80
16	H	4-F	84	195-197 dec. (DMSO-Acetic Acid) (b)	C <sub>17</sub> H <sub>12</sub> FNOS	61.99	61.88	3.67	3.76
17	H	4-OCH <sub>3</sub>	98	143-145 dec. (DMSO-Acetic Acid) (b)	C <sub>18</sub> H <sub>15</sub> NO <sub>4</sub> S	63.32	63.49	4.43	4.40
18	CH <sub>3</sub>	H	97	150.5-151.5 (Benzene-Hexane)	C <sub>18</sub> H <sub>15</sub> NO <sub>3</sub> S	66.44	66.38	4.65	4.46
19	CH <sub>2</sub>	4-Cl	69	143-145 (Benzene-Hexane)	C <sub>18</sub> H <sub>14</sub> ClNO <sub>3</sub> S	60.08	60.07	3.92	3.98
20	CH <sub>3</sub>	3-F	91	145-146 (Benzene-Hexane)	C <sub>18</sub> H <sub>14</sub> FNOS	62.96	62.97	4.11	4.31
21	CH <sub>3</sub>	4-F	88	158.5-159.5 (Benzene-Hexane)	C <sub>18</sub> H <sub>14</sub> FNOS	62.96	62.64	4.11	4.18
22	CH <sub>3</sub>	4-OCH <sub>3</sub>	93	133-135 (Ethyl Acetate)	C <sub>19</sub> H <sub>17</sub> NO <sub>4</sub> S	64.39	64.20	4.84	4.92

(a) Crude but essentially pure material. (b) Recrystallized by dissolving the dry acid in a small volume of DMSO and diluting with the specified cosolvent. The decomposition point of this acid was somewhat dependent on the rate of heating which in this determination was approximately 10°/minute.

Table 3  
Benzyl 2-(3-Carboxyquinolyl) Sulfones and Methyl Esters




Compound	R <sub>1</sub>	R <sub>2</sub>	Yield %	M.p. °C (Recrystallization Solvent)	Formula	C		H		N	
						Calcd.	Found	Calcd.	Found	Calcd.	Found
<b>23</b>	H	H	65 (a)	198-202 dec. (DMSO-Acetic Acid) (b)	C <sub>17</sub> H <sub>13</sub> NO <sub>4</sub> S	62.37	62.02	4.00	4.20	4.28	4.38
<b>24</b>	H	4-Cl	69 (a)	209-211 dec. (DMSO-Methanol) (b)	C <sub>17</sub> H <sub>12</sub> ClNO <sub>4</sub> S	56.43	56.68	3.34	3.20	3.87	3.67
<b>25</b>	H	3-F	80 (a)	205-209 dec. (DMSO-Acetic Acid) (b)	C <sub>17</sub> H <sub>12</sub> FNO <sub>4</sub> S	59.12	59.02	3.50	3.62	4.06	3.99
<b>26</b>	H	4-F	65 (a)	204-207 dec. (DMSO-Acetic Acid) (b)	C <sub>17</sub> H <sub>12</sub> FNO <sub>4</sub> S	59.12	58.99	3.50	3.64	4.06	4.13
<b>27</b>	H	4-OCH <sub>3</sub>	12 (a)	184-186 dec. (DMSO-Acetic Acid) (b)	C <sub>18</sub> H <sub>15</sub> NO <sub>5</sub> S	60.49	60.66	4.23	4.14	3.92	3.63
<b>28</b>	CH <sub>3</sub>	H	84 (c)	152-5-153.5 (Benzene-Hexane)	C <sub>18</sub> H <sub>15</sub> NO <sub>4</sub> S	63.33	63.06	4.43	4.56	4.10	4.08
<b>29</b>	CH <sub>3</sub>	4-Cl	83 (c)	126-128 (Benzene-Hexane)	C <sub>16</sub> H <sub>14</sub> ClNO <sub>4</sub> S	57.52	57.84	3.75	3.89	3.73	4.11
<b>30</b>	CH <sub>3</sub>	3-F	78 (c)	157.5-158.5 (Benzene-Hexane)	C <sub>18</sub> H <sub>14</sub> FNO <sub>4</sub> S	60.16	60.25	3.93	3.91	3.90	3.86
<b>31</b>	CH <sub>3</sub>	4-F	87 (c)	156.5-157.5 (2-Propanol)	C <sub>18</sub> H <sub>14</sub> FNO <sub>4</sub> S	60.16	60.11	3.93	4.09	3.90	3.99
<b>32</b>	CH <sub>3</sub>	4-OCH <sub>3</sub>	44 (c,d)	110-112 (Ethanol)	C <sub>19</sub> H <sub>17</sub> NO <sub>5</sub> S	61.44	61.49	4.61	4.56	3.77	3.74

(a) Crude but essentially pure material. (b) Recrystallized by dissolving the dry acid in a small volume of DMSO and adding several volumes of the specified cosolvent. The decomposition point of this acid was somewhat dependent on the rate of heating which in this case was approximately 10°/minute. (c) Recrystallized. (d) By oxidation of ester **12** with *m*-chloroperbenzoic acid.


TABLE 4

2-Aryl-3-hydroxythieno[2,3-*b*]quinoline 1,1-Dioxides and Sodium Salts



Compound	R <sub>1</sub>	R <sub>2</sub>	Yield %	M.p. °C (Recrystallization Solvent)	Formula	C		H		N	
						Calcd.	Found	Calcd.	Found	Calcd.	Found
<b>33</b>	Na	H	84 (b)	> 320 (Methanol)	C <sub>17</sub> H <sub>10</sub> NO <sub>3</sub> SNa	61.62	61.54	3.04	3.12	4.23	4.29
<b>34</b>	Na	4-Cl	94 (b)	> 320 (Ethanol)	C <sub>17</sub> H <sub>9</sub> ClNO <sub>3</sub> SNa	55.82	55.55	2.48	2.58	3.83	3.72
<b>35</b>	Na	3-F	94 (b)	> 320 (Methanol)	C <sub>17</sub> H <sub>9</sub> FNO <sub>3</sub> SNa	58.45	58.48	2.60	2.48	4.01	4.11
<b>36</b>	Na	4-F	86 (b)	> 320 (Methanol)	C <sub>17</sub> H <sub>9</sub> FNO <sub>3</sub> SNa	58.45	58.57	2.60	2.48	4.01	4.07
<b>37</b>	Na	4-OCH <sub>3</sub>	(c)	> 320 (Methanol)	C <sub>18</sub> H <sub>12</sub> NO <sub>4</sub> SNa	59.83	59.93	3.35	3.53	3.88	3.90
<b>38</b>	H	H	(d)	240.5-242.5 (Acetic Acid)	C <sub>17</sub> H <sub>11</sub> NO <sub>3</sub> S	66.00	66.12	3.59	3.82	4.53	4.68
<b>39</b>	H	4-Cl	(d)	242.5-244.5 (Acetic Acid)	C <sub>17</sub> H <sub>10</sub> ClNO <sub>3</sub> S	59.40	59.59	2.93	3.07	4.08	4.20
<b>40</b>	H	3-F	(d)	241-243 (Acetic Acid)	C <sub>17</sub> H <sub>10</sub> FNO <sub>3</sub> S	62.38	62.23	3.08	3.03	4.28	4.12
<b>41</b>	H	4-F	(d)	228-230 (Acetic Acid)	C <sub>17</sub> H <sub>10</sub> FNO <sub>3</sub> S	62.38	62.33	3.08	3.19	4.23	4.37
<b>42</b>	H	4-OCH <sub>3</sub>	74 (e)	226.5-228.5 (Acetic Acid)	C <sub>18</sub> H <sub>13</sub> NO <sub>4</sub> S	63.70	63.40	3.86	3.97	4.13	4.36

(a) Crude but essentially pure material. (b) After drying to constant weight in high vacuum at 150°. (c) Isolated as **42**. (d) Essentially quantitative by acidification (excess 37% hydrochloric acid) of a 1:1 methanol-water solution of the corresponding sodium salt and dilution with water. (e) By acidification of the reaction mixture with 37% hydrochloric acid.



potentially serious competing reactions were anticipated (see below), treatment of **28-32** with sodium methoxide was expected to yield the sodium salts **33-37**, since precedent for a similar cyclization exists in non-heterocyclic systems (6-8).

Accordingly, S-benylation of **3** with various benzyl chlorides, employing a modification of the method of Hull (3), gave the sulfides **4-8** in high yield. Initial exploratory work (Scheme 1) with **4** indicated that the aldehyde function could be oxidized to the acid **9** with silver oxide in aqueous tetrahydrofuran. The sulfone ester **28** was then found to result from esterification of **9** with diazomethane, followed by oxidation of the resulting sulfide-ester **10** with a slight excess of *m*-chloroperbenzoic acid in chloroform. Although the results of this exploratory work appeared promising, we initially desired a convenient procedure for the direct oxidation of **4-8** to sulfone-acids **23-27** (Scheme 2). A possible reagent for this transformation appeared to be potassium permanganate. However, we were interested in avoiding the potential experimental difficulties (9) associated with large scale oxidations of this type. In the course of investigating other possible reagents, we found that when the sulfides **4-8** were treated with slightly more than the calculated amount (1.1 molar equivalents) of sodium chlorite in 90% pyridine containing a catalytic amount of 37% hydrochloric acid, the sulfide function was exothermically oxidized in 20 minutes to the corresponding sulfoxide with concomitant oxidation of the aldehyde function to the carboxylic acid. The resulting sulfoxide-acids **13-17** were obtained in high yield with essentially no over-oxidation to the sulfones and were readily esterified with diazomethane to the corresponding esters **18-22**.

In each case the nmr spectrum of the sulfoxides **13-22** showed a well-defined AB system for the methylene protons. Magnetic nonequivalence of methylene protons adjacent to a sulfoxide function is well known (10-13). However, a number of examples of apparent equivalence of such protons have been reported in systems similar to

**13-22** (14-16). For example, Nishio (15,16) reported that for certain members of a series of benzyl phenyl sulfoxides in deuteriochloroform (and other solvents), no geminal coupling of the methylene protons was observed and thus these protons appeared to be equivalent. The magnetic nonequivalence of methylene protons in this series was found to have a strong, complicated dependence on the dielectric constant of the solvent and the electronic nature of the aromatic substituents. Although we have not made a detailed study of solvent effects, no apparent equivalence or near equivalence of the methylene protons of **13-17** (in dimethyl sulfoxide- $d_6$ ) or of **18-22** (in deuteriochloroform) was observed. In the sulfoxides **13-22**, separation of the methylene protons was in the range 0.40-0.64  $\delta$  and the observed coupling constants for these protons ( $J = 12.0$ - $13.0$  Hz) were of the magnitude expected.

Except in the case of the 4-methoxybenzyl derivative, **27**, the sulfone acids **23-27** were also obtained in good yield when the sulfides **4-8** were oxidized with excess (3.2 molar equivalents) of sodium chlorite at 80-90° for 1.5 hours. Esterification of these acids with diazomethane then provided the direct precursors, **28-32**, of the sodium salts **33-37** of **38-42**.

A search of the literature revealed that sodium chlorite has been utilized for the oxidation of phenolic aldehydes to the corresponding acids (17) and in the oxidation of carbohydrates (18) but otherwise has received little attention (19) in preparative organic chemistry. To our knowledge, no examples of the oxidation of sulfides to sulfoxides and sulfones using this reagent have been reported. In view of the successful applications described above (except efficient conversion of **8** to **27**, see below) this material provides a new reagent for this stepwise oxidative sequence and may be especially valuable when concomitant oxidation of the aldehyde and sulfide function is desired. The scope of this reaction is under investigation and will be reported in due course.

Although the sulfone acid **27** could be obtained directly from the sulfide **8** by this method, the required ester **32**, of **27** was best prepared using the two-stage oxidative sequence initially employed for conversion of **4** to **28** (Scheme 1).

Cyclization of sulfone esters similar to **28-32** has been easily accomplished previously with sodium methoxide in methanol (6-8); however, this precedent was established for non-heterocyclic precursors to the cyclic  $\beta$ -keto-sulfones. We considered displacement of the sulfonyl group in **28-32**, or in the cyclized materials **33-37**, by methoxide ion as possible competing reactions in view of the kinetic results of Barlen (20) who found that methoxide ion readily displaced the methanesulfonyl group located in the 2- and 4-positions of the quinoline nucleus.

Table 5 (a)

## Inhibition of Bovine Heart Phosphodiesterase

Compound (b)	$I_{50} \times 10^4 \text{ M (c,d)}$
<b>33</b>	3.6 (2.4-4.7)
<b>34</b>	2.2 (1.6-2.8)
<b>35</b>	2.3 (1.5-3.2)
<b>36</b>	3.5 (1.7-5.3)
<b>37</b>	4.6 (2.9-6.3)
Indomethacin	1.9 (1.3-2.5)
Theophylline	6.2 (5.0-7.3)

(a) For procedure see experimental. (b) Compounds **23-25** at 500  $\mu\text{M}$  showed less than 10% inhibition. (c) Numbers in parentheses represent the 95% confidence intervals. (d) Substrate concentration was 100  $\mu\text{M}$ .

In order to avoid possible complications of this type, we employed only a slight excess of sodium methoxide and short (0.5 hour) reaction time for the cyclization of **28-32** and were able to obtain the sodium salts **33-37** in high yield. The conjugate acids **38-42**, obtained by acidification of aqueous methanolic solutions of the sodium salts appear to exist in the enol form (hydroxyl and no carbonyl absorption in the infrared). These compounds easily dissolved in aqueous sodium hydroxide to regenerate the corresponding sodium salts **33-37** but were difficultly soluble in the usual organic solvents and consequently not readily recrystallized. In contrast, the sodium salts **33-37** were bright orange solids which except **34**, were readily recrystallized from methanol and were obtained as methanol solvates. The compounds tenaciously retained methanol of crystallization which could be completely removed only by drying in high vacuum at 150-160°.

## Biological.

Because of their similarity to a series of antiinflammatory **1** and **2** (6), we expected that **33-42** might possess significant antiinflammatory activity. Furthermore, because of the large sample requirements for *in vivo* evaluation we sought a simple *in vitro* test to guide our synthetic efforts in target compound selection. Stefanovich (21) has reported that the potency of acidic antiinflammatory agents correlates well with their ability to inhibit bovine heart cyclic AMP phosphodiesterase. The anti-phosphodiesterase effects of nonsteroidal antiinflammatory agents has been recently reviewed (22).

Compounds **33-37** (Table 5, the salts were used due to greater solubility) were indomethacin-like in their ability to inhibit the enzyme and significantly more potent than the standard phosphodiesterase inhibitor, theophylline. Open ring analogs **23-26** were inactive. Changes in the substitution pattern on the phenyl substituent had relatively little effect on  $I_{50}$ .

Using the carrageenan rat paw edema test essentially as described by Winter (23), **38-42** failed to show significant acute antiinflammatory activity. Thus, in this series our results indicate no correlation between inhibition of phosphodiesterase and *in vivo* antiinflammatory activity. These compounds were also essentially inactive in the mouse phenylquinone-induced writhing test (24) for analgesia, but do constitute a potent new class of cyclic AMP phosphodiesterase inhibitors.

## EXPERIMENTAL

Melting points (corrected) were determined in open capillary tubes. Microanalyses were performed by the Laboratory's Section on Microanalytical Services and Instrumentation. Ir (Perkin-Elmer 21), mass (Hitachi Perkin-Elmer RMU-6E; 70 ev) and nmr (Varian A-60; TMS internal reference) spectra were consistent with the assigned structures. Sodium chlorite (80%) was purchased from Alpha Products division of Ventron Corporation, Danvers, MA 01923. Optimization of yields was not attempted in this work. Bovine heart phosphodiesterase was purchased from Sigma Chemical Co.; [ $8\text{-}^3\text{H}$ ]cyclic AMP, specific activity 30 Ci/mmol, was obtained from Amersham Searle Corp.; [ $14\text{C}$ ] 5'-AMP, specific activity 570 mCi/mmol, was obtained from New England Nuclear Co.

## Enzyme Studies.

The assay procedure of Klee (25) was used in this work. The cyclic AMP phosphodiesterase was shown *via* a Lineweaver-Burke plot to contain both high and low  $K_m$  activities comparable to those reported (26,27). Initial rate measurements were linear with enzyme concentration and time (to 40 minutes). Inhibitor studies were conducted at a cyclic AMP concentration of 100  $\mu\text{M}$ .  $I_{50}$ 's were determined by plotting uninhibited velocity/inhibited velocity ( $V_o/V_i$ ) versus inhibitor concentration (28). The  $I_{50}$  is the inhibitor concentration giving  $V_o/V_i = 2$ . Normally, five inhibitor concentrations giving 25-75% inhibition of the enzyme were used. Each assay was repeated with fresh inhibitor solutions and data was pooled. The 95% confidence intervals for the  $I_{50}$ 's were determined from the 95% confidence intervals for the line generated by the  $V_o/V_i$  versus inhibitor concentration plots. An equivalent of sodium hydroxide solution was used to solubilize indomethacin. The buffer capacity of the assay buffer (0.05 N Tris, pH 8.0) was sufficient to resist potential pH changes that could be caused by the inhibitors.

Benzyl 2-(3-Formylquinolyl) Sulfides (**4-8**). (Table 1).

These compounds were prepared from 3-formylquinoline-2-thiol (**3**) (3). The general procedure for 3-fluorobenzyl 2-(3-formylquinolyl) sulfide (**6**) was developed from, and gave better results than, that employed by Hull (3) for synthesis of **4**.

To a stirred suspension of the thiol **3** (9.45 g., 50.0 mmoles) in dry dimethylformamide (150 ml.) was added sodium methoxide (2.85 g., 52.7 mmoles). The reaction mixture was warmed to 40° and stirred several minutes until the solids had dissolved. To the resulting blood-red solution was added 3-fluorobenzyl chloride (8.64 g., 60 mmoles). A moderately exothermic reaction ensued, and the initial red color was rapidly discharged to give a light orange solution. After stirring 0.5 hours, 10% sodium hydroxide (100 ml.) was added, followed by sufficient ice to give a final volume of 500 ml. The resulting solid material was filtered, washed well with water, then hexane and dried to give crude, nearly pure **6** (13.6 g., 92%), m.p. 123-135.5°. Recrystallization

gave pure **6**; mass spectrum:  $m/e$  297 ( $M^+$ ); ir (nujol):  $1685\text{ cm}^{-1}$  ( $C=O$ ); nmr (deuteriochloroform):  $\delta$  4.62 (s, 2H,  $CH_2$ ), 6.66-8.16 (m, 8H, ArH), 8.40 (s, 1H, quinoline-4H), and 10.26 (s, 1H, CHO).

Benzyl 2-(3-Carboxyquinolyl) Sulfoxides (**13-17**) and the Corresponding Methyl Esters **18-22**.

The following procedure for 3-fluorobenzyl 2-(3-carboxyquinolyl) sulfoxide (**15**) and the corresponding methyl ester **20** is representative.

The crude sulfide **6** (892 mg., 3.0 mmoles) was dissolved in a solution of pyridine (15 ml.) and water (3 ml.). After addition of 37% hydrochloric acid (2 drops), a solution of 80% sodium chlorite (373 mg., 3.3 mmoles) in water (3 ml.) was added dropwise with cooling to maintain the temperature of the reaction mixture in the range  $22-28^\circ$ . After stirring 0.5 hour, the mixture was diluted with water (100 ml.) and extracted with ether (100 ml.). The aqueous phase was removed, acidified with 37% hydrochloric acid, and the resulting white solid was filtered, washed well with water and dried to give essentially pure **15** (869 mg., 88%). The analytical sample was prepared by dissolving the dry material in warm dimethyl sulfoxide and diluting with three volumes of methanol; mass spectrum:  $m/e$  329 ( $M^+$ ); ir (nujol):  $1695\text{ cm}^{-1}$  ( $C=O$ ); nmr (DMSO- $d_6$ ):  $\delta$  3.99 and 4.58 (1H each, AB quartet centered at 4.28,  $J = 13.0\text{ Hz}$ ,  $CH_2S=O$ ), 7.00-7.58 (m, 4H, ArH), 7.73-8.50 (m, 4H, ArH) and 9.13 (s, 1H, quinoline-4H). Treatment of **15** (576 mg., 1.75 mmoles) with excess diazomethane in ether-chloroform gave the methyl ester **20** (545 mg., 91%) after recrystallization from benzene-hexane; mass spectrum:  $m/e$  343 ( $M^+$ ); ir (nujol):  $1710\text{ cm}^{-1}$  ( $C=O$ ); nmr (deuteriochloroform):  $\delta$  4.05 (s, 3H,  $OCH_3$ ), 4.08 and 4.60 (1H each, AB quartet centered at 4.33,  $J = 12.5\text{ Hz}$ ,  $CH_2S=O$ ), 6.90-7.40 (m, 4H, ArH), 7.66-8.63 (m, 4H, ArH) and 9.05 (s, 1H, quinoline-4H).

Benzyl 2-(3-Carboxyquinolyl) Sulfones (**23-27**) and the Corresponding Methyl Esters **28-32**.

These compounds were prepared using the general procedure described below for 3-fluorobenzyl 2-(3-carboxyquinolyl) sulfone (**25**) and the corresponding methyl ester **30**.

The sulfide **6** (10.40 g., 35.0 mmoles) was dissolved in a mixture of pyridine (100 ml.), water (20 ml.) and 37% hydrochloric acid (0.5 ml.). A solution of 80% sodium chlorite (13.05 g., 115.5 mmoles) in water (50 ml.) was added dropwise (stirring) with cooling to maintain a temperature of  $<50^\circ$ . When the addition was complete the stirred solution was heated at  $75-85^\circ$  for 1.5 hours, cooled, diluted with water (200 ml.) and extracted with ether (200 ml.) which was discarded. The aqueous phase was acidified with 37% hydrochloric acid and the resulting solid was filtered, washed well with water and dried to give nearly pure **25** (9.68 g., 80%). For recrystallization, **25** was dissolved in warm dimethylsulfoxide and the solution was diluted with three volumes of acetic acid to give pure **25**; mass spectrum:  $m/e$  345 ( $M^+$ ); ir (nujol):  $1715\text{ cm}^{-1}$  ( $CO_2H$ ); nmr (DMSO- $d_6$ ):  $\delta$  5.23 (s, 2H,  $CH_2$ ), 7.00-8.63 (m, 8H, ArH) and 9.00 (s, 1H, quinoline-4H). Treatment of the sulfone-acid **25** (690 mg., 2.0 mmoles) with excess diazomethane in ether-chloroform gave the corresponding ester **30** (563 mg., 78%) after recrystallization from benzene-hexane; mass spectrum:  $m/e$  359 ( $M^+$ ); ir (nujol):  $1712\text{ cm}^{-1}$  ( $C=O$ ); nmr (deuteriochloroform):  $\delta$  4.02 (s, 3H,  $OCH_3$ ), 4.98 (s, 2H,  $CH_2$ ), 6.88-7.40 (m, 4H, ArH), 7.68-8.46 (m, 4H, ArH) and 8.63 (s, 1H, quinoline-4H).

Sodium Salts of 2-Aryl-3-hydroxythieno[2,3-*b*]quinoline 1,1-Dioxides (**33-37**) and Conjugate Acids **38-42**.

The sulfone esters **28-32** were cyclized to the corresponding sodium salts **33-37** using the following general procedure for the cyclization of **30**.

The sulfone-ester **30** (1.078 g., 3.0 mmoles) was added in one portion to a stirred solution of sodium methoxide (at  $25-30^\circ$ ) prepared by dissolving clean sodium (80 mg., 3.48 eq.) in dry methanol (15.0 ml.). The solution immediately took on a yellow-orange color as the solid began to dissolve. The stirred mixture was refluxed 0.5 hours during which time the color became deep orange and crystalline material separated from the solution. The solution was cooled, filtered and the resulting orange solid was washed with cold methanol and air dried to give **35**· $CH_3OH$  (1.070 g., 94%). Unsolvated **35** was obtained by drying the solvate for 2 hours at  $150-160^\circ$  in high vacuum. Calcd. weight loss: 8.40%. Found: 8.13%; ir (potassium bromide): 1570, 1531, 1240 and  $1115\text{ cm}^{-1}$ ; nmr (DMSO- $d_6$ ):  $\delta$  6.46-8.40 (m, 8H, ArH), 8.46 (s, 1H, H-4). Acidification of a solution of **35** in methanol-water (1:1) gave the conjugate acid **40** in essentially quantitative yield. Two recrystallizations provided pure material; mass spectrum:  $m/e$  327 ( $M^+$ ), 263 ( $M^+ - SO_2$ ); ir (potassium bromide): 3150 (OH), 1600, 1575, 1295, 1230 and  $1103\text{ cm}^{-1}$ ; nmr (DMSO- $d_6$ ):  $\delta$  7.03-8.38 (m, 9H, ArH+OH) 8.91 (s, 1H, quinoline-4H).

Benzyl 2-(3-Carboxyquinolyl) Sulfides (**9** and **11**) and the Corresponding Methyl Esters (**10** and **12**).

The procedure described below for 4-methoxybenzyl 2-(3-carboxyquinolyl) sulfide **11** was also used for the preparation of **9**.

A solution of sodium hydroxide (3.2 g., 80.0 mmoles) in distilled water (25 ml.) was added to a stirred solution of silver nitrate (6.8 g., 40.0 mmoles) in distilled water (175 ml.). The sulfide-aldehyde **8** (5.58 g., 18 mmoles) in tetrahydrofuran (200 ml.) was added and stirring was continued 3 hours. The mixture was then filtered through celite, diluted with water and acidified with acetic acid. The resulting solid was filtered, washed well with water and dried to give essentially pure **11** (5.80 g., 99%). Recrystallization gave pure material which showed the following spectral properties. Mass spectrum:  $m/e$  325 ( $M^+$ ); ir (potassium bromide):  $1680\text{ cm}^{-1}$  ( $C=O$ ); nmr (DMSO- $d_6$ ):  $\delta$  3.71 (s, 3H,  $OCH_3$ ) and 4.48 (s, 2H,  $CH_2S$ ), 6.86 (d, 2H,  $J = 8.8\text{ Hz}$ , ArH), 7.31-8.16 (m, 6H, ArH including d, 2H, at  $\delta$  7.45,  $J = 8.8\text{ Hz}$ ) and 8.88 (s, 1H, quinoline-4H). The acids **9** (2.90 g., 9.8 mmoles) and **11** (5.0 g., 15.4 mmoles) were esterified with excess diazomethane in chloroform-ether to give the esters **10** (2.93 g., 92%) and **12** (4.60 g., 88%), respectively. Two recrystallizations of **12** gave the analytical sample for which the spectral properties described below were observed; mass spectrum:  $m/e$  339 ( $M^+$ ); ir (potassium bromide):  $1709\text{ cm}^{-1}$  ( $C=O$ ); nmr (deuteriochloroform):  $\delta$  3.75 (s, 3H,  $OCH_3$ ), 3.96 (s, 3H,  $OCH_3$ ) and 4.55 (s, 2H,  $SCH_2$ ), 6.78 (d, 2H,  $J = 8.8\text{ Hz}$ , ArH), 7.20-8.10 (m, 6H, ArH including d, 2H, at 7.40,  $J = 8.8\text{ Hz}$ ), 8.66 (s, 1H, quinoline-4H).

4-Methoxybenzyl 2-(3-Carbomethoxyquinolyl) Sulfone (**32**) by Oxidation of the Sulfide **12**.

To a stirred solution of the sulfide-ester **12** (9.3 g., 27.4 mmoles) in chloroform (350 ml.) was added solid 85% *m*-chloroperbenzoic acid (12.14 g., 60 mmoles) during 0.5 hours while maintaining a temperature range of  $25-34^\circ$ . A second portion of 85% *m*-chloroperbenzoic acid (2.0 g., 9.8 mmoles) was added after 18 hours and stirring was continued for an additional 3 hours. The solution was then washed successively with 10% sodium bisulfite (2 x 100 ml.), 7% sodium bicarbonate (3 x 100 ml.), water (100 ml.) and dried with magnesium sulfate. Evapora-

tion of the solvent gave a solid residue which was recrystallized twice to give pure **32** (4.47 g., 44%); mass spectrum:  $m/e$  371 ( $M^+$ ); ir (potassium bromide):  $1711\text{ cm}^{-1}$  (C=O); nmr (deuteriochloroform):  $\delta$  3.71 (s, 3H, OCH<sub>3</sub>), 3.98 (s, 3H, OCH<sub>3</sub>), 4.90 (s, 2H, SO<sub>2</sub>CH<sub>2</sub>), 6.78 (d, 2H,  $J = 8.9\text{ Hz}$ , ArH), 7.35 (d, 2H,  $J = 8.9\text{ Hz}$ , ArH) 7.50-8.40 (m, 4H, ArH) and 8.55 (s, 1H, quinoline-4H).

#### Acknowledgments.

The authors wish to thank Mr. William Landis for determination of the mass spectra and Mrs. Alice Wong for elemental analyses. We also thank Dr. E. L. May for his encouragement during this work. One of us (E. A. H.) wished to thank Dr. May for the opportunity to spend a sabbatical year in his laboratory. This work was supported in part by an A. D. Williams Fluid Fund grant, Medical College of Virginia, Virginia Commonwealth University. The authors also wish to thank Dr. William J. Novick, Jr., Hoechst-Roussel Pharmaceuticals Inc. for the *in vivo* data.

#### REFERENCES AND NOTES

- (1) Guest worker on Sabbatical leave from the Department of Chemistry, The Pennsylvania State University, York Campus, York, Pennsylvania, 17403.
- (2) Y. Kuwayama, *Yakugaku Zasshi*, **82**, 1028 (1962); *Chem. Abstr.*, **58**, 5687g (1963). For a related paper see: G. Kobayashi, Y. Kuwayama and S. Okamura, *Yakugaku Zasshi*, **83**, 234 (1963); *Chem. Abstr.*, **59**, 5144d (1963).
- (3) R. Hull, *J. Chem. Soc., Perkin Trans. I*, 2911 (1973).
- (4) T. Jen, B. Dicnel, F. Dowalo, H. V. Hloeven, P. Bender, and B. Loev, *J. Med. Chem.*, **16**, 633 (1973).
- (5) P. Shanmugam, K. Kanakarajan, N. Soundararajan and A. Gnanasekaran, *Synthesis*, 253 (1976).
- (6) J. G. Lombardino and E. H. Wiseman, *J. Med. Chem.*, **13**, 206 (1970).
- (7) A. Cohen and S. Smiles, *J. Chem. Soc.*, 406 (1930).
- (8) A. H. Lamberton and J. E. Thorpe, *J. Chem. Soc., (C)*, 2571 (1967).
- (9) M. Fieser and L. F. Fieser, "Reagents for Organic Synthesis", Vol. 1, John Wiley and Sons, Inc., New York, N.Y., 1967, p. 942.
- (10) T. D. Coyle and F. G. A. Stone, *J. Am. Chem. Soc.*, **83**, 4138 (1961).
- (11) J. S. Waugh and F. A. Cotton, *J. Phys. Chem.*, **65**, 562 (1961).
- (12) K. Griesbaum, A. A. Oswald and B. E. Hudson, *J. Am. Chem. Soc.*, **85**, 1969 (1963).
- (13) M. Nishio and T. Ito, *Chem. Pharm. Bull.*, **13**, 1392 (1965).
- (14) I. Sataty, *Org. Magn. Reson.*, **3**, 429 (1971).
- (15) M. Nishio, *Chem. Pharm. Bull.*, **15**, 1669 (1967).
- (16) M. Nishio, *ibid.*, **17**, 262 (1969).
- (17) B. O. Lindgren and T. Nilsson, *Acta. Chem. Scand.*, **27**, 888 (1973).
- (18) T. P. Nevell, *Methods Carbohydr. Chem.*, **3**, 182 (1963).
- (19) Oxidation of a number of organic compounds with sodium chlorite has been reported by a Polish group. However, these investigations were in general concerned with product distribution ratios and were not of a preparative nature. An exception to this was oxidation of hydroquinone to quinone in high yield. See K. Paluch and I. Banska, *Rocz. Chem.*, **45**, 2187 (1971); *Chem. Abstr.*, **76**, 126536s (1972). For examples of product distribution ratio studies see: K. Paluch, J. Baran and J. Otto, *Rocz. Chem.*, **46**, 509 (1972); *Chem. Abstr.*, **77**, 19285h (1972); J. Otto and K. Paluch, *Rocz. Chem.*, **46**, 1551 (1972); *Chem. Abstr.*, **78**, 57909t (1973).
- (20) G. B. Barlen and W. V. Brown, *J. Chem. Soc., (B)*, 736 (1967).
- (21) V. Stefanovich, *Res. Commun. Chem. Pathol. Pharmacol.*, **7**, 573 (1974).
- (22) M. Chasin and D. N. Harris, *Adv. Cyclic Nucleotide Res.*, **7**, 225 (1976).
- (23) C. A. Winter, E. A. Risley and G. W. Nuss, *Proc. Soc. Exp. Biol. Med.*, **111**, 544 (1962).
- (24) E. Siegmund, R. Cadmus and G. Lu, *Proc. Soc. Expt. Biol. Med.*, **95**, 729 (1957).
- (25) C. B. Klec, *Biochemistry*, **16**, 1017 (1977).
- (26) J. A. Beavo, J. G. Hardman and E. W. Sutherland, *J. Biol. Chem.*, **245**, 5649 (1970).
- (27) S. M. Hecht, R. D. Faulkner and S. D. Hawrelak, *Proc. Nat. Acad. Sci., USA*, **71**, 4670 (1974).
- (28) B. R. Baker, W. W. Lee, W. S. Skinner, A. P. Martinez and E. Tong, *J. Med. Pharm. Chem.*, **2**, 633 (1960).